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COMMENTARY
Biologic Agents to Promote Periodontal Regeneration and Bone
Augmentation
Jill D. Bashutski* and Hom-Lay Wang*
Periodontal regeneration is preferred over tissue repair and is accomplished through the exclusion of epithelial tissues,
which allows cementum, bone, and connective tissue to repopulate the wound. Recently, biologic materials have emerged as
adjuncts to aid in regeneration by augmenting the events of wound healing in the area. A review of biologic agentswas conducted
using the following MeSH terms: guided tissue regeneration, intercellular signaling peptides and proteins, and biologic factors.
Enamel matrix derivative (EMD), platelet-derived growth factor (PDGF), platelet-rich plasma, bone morphogenetic proteins
(BMPs), fibroblast growth factor (FGF), and parathyroid hormone (PTH) have all shown promise in promoting hard- or soft-tissue
regeneration. No biologic agent is ideal for all clinical situations so the clinician must evaluate each situation to identify the best
indication for its usage. Currently, EMD and PDGF have Food and Drug Administration approval for periodontal regeneration,
whereas BMP-2 is approved for bone augmentation. FGF and PTH do not have Food and Drug Administration approval for
periodontal applications and so their clinical usage is not indicated. Clin Adv Periodontics 2011;1:80-87.
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Background
Newer approaches to periodontal therapy include re-
generative procedures that aim to restore lost periodontal
ligament, bone, cementum, and connective tissue. When
the goal is to restore periodontal tissues around teeth, this
is referred to as guided tissue regeneration (GTR). Guided
bone regeneration (GBR) is also used to provide bone
augmentation in edentulous areas, usually before implant
placement. Regenerative therapy has an advantage over
traditional surgical approaches in that the original tissues
are reestablished, not replaced through a reparative pro-
cess. Regenerative procedures typically use barrier mem-
branes and bone grafting materials to encourage the
growth of key periodontal tissues but exclude unwanted
cell types, such as epithelial cells and connective tissue
fibroblasts.1-4 Although regenerative therapies have great
potential, they remain unpredictable in their ability to
produce acceptable outcomes in all situations consistently.
Laurell et al.5 showed that, when a bone graft alone was
placed in infrabony periodontal defects, limited pocket
reduction was achieved but clinical attachment level
(CAL) gain and bone fill were significantly improved,
averaging 2.1 mm. When GTR with both bone graft and
a membrane were used, GTR resulted in significant pocket
reduction, CAL gain of 4.2 mm, and bone fill averaging
3.2 mm.5 The predictability of GTR, however, has been
questioned. Eikholz et al.6 treated 50 infrabony defects
with GTR. After 5 years, 47 of the defects still showed
evidence of vertical attachment gain, but three defects had
a net loss of up to 2.2 mm. In a systematic review of the
literature, Murphy and Gunsolley7 found some heteroge-
neity in the outcome of GTR and concluded that it was
difficult to assess the efficacy of periodontal treatment
using physical barriers because no studies were performed
that measured tooth retention for>5 years. Consequently,
a need exists to augment current GTR techniques to
improve outcomes and predictability.
To help promote periodontal regeneration and healing,
the local application of biologic modifiers such as growth
factors has been investigated. These agents act by augment-
ing the wound healing process through anabolic bone
formation, angiogenesis, cementogenesis, osteoblast differ-
entiation, mitosis, chemotaxis, and other processes that
improve the healing environment. Biologic modifiers, in-
cluding enamel matrix derivative (EMD), platelet-derived
growth factor (PDGF), bone morphogenetic protein
(BMP), platelet-rich plasma (PRP), fibroblast growth fac-
tor (FGF), and parathyroid hormone (PTH), have all
shown promise in enhancing regeneration.8-12 When
choosingwhich agent to use, it is important to consider sev-
eral factors, including the evidence supporting its use as
well as the specific clinical situation. An electronic litera-
ture search of biologic agents was conducted in the
PubMed (MEDLINE) database using the following MeSH
terms: guided tissue regeneration, intercellular signaling
peptides and proteins, and biologic factors. Other key
search terms included bone morphogenic proteins, para-
thyroid hormone, platelet-derived growth factor, enamel
matrix derivative, fibroblast growth factor, platelet-rich
plasma, and related terms. Animal and human studies pub-
lished in the English language up to January 2011 were re-
viewed. This paper presents an overview of the different
* Department of Periodontics and Oral Medicine, School of Dentistry,
University of Michigan, Ann Arbor, MI.
Submitted April 24, 2011; accepted for publication June 8, 2011
doi: 10.1902/cap.2011.110044
80 Clinical Advances in Periodontics, Vol. 1, No. 2, August 2011
biologic agents that can be used as adjuncts for GTR and
GBR as well as a decision model for deciding on the best
agent for a given clinical scenario (Fig. 1).
Enamel Matrix Derivative
Physiologically, enamel matrix proteins are secreted by
Hertwig’s epithelial root sheath during root development
and serve to promote cementogenesis.13 A recent review
by Bosshardt14 suggests that there is strong evidence for
enamel matrix proteins to support wound healing and
new periodontal tissue formation, but that the biologic
mechanism by which this occurs is still unclear. A commer-
cially available form of EMD† is available and is derived
from porcine tooth buds, and is approved by the Food
and Drug Administration (FDA) for the treatment of mod-
erate or severe periodontitis as well as to optimize tissue
FIGURE 1 Summary of the mechanism of action, indications, and FDA approval status of common biologic agents to promote periodontal regeneration.
TCP ¼ tricalcium phosphate.
† Emdogain, Straumann, Basel, Sweden.
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height in esthetic zones. It is only approved for intrabony
defects, not furcation areas, although there is evidence that
EMD is effective in treating grade 2 furcations.15,16 EMD is
perhaps one of the most extensively studied biologic
agents, and Table 1 summarizes some key studies evaluat-
ing the use of EMD to promote regeneration.
Platelet-Derived Growth Factor
PDGF-BB is a growth factor involved in wound healing
that stimulates the regenerative potential of periodontal
tissues, including bone, cementum, and periodontal liga-
ment.17 The commercially available form‡ is FDA ap-
proved for the treatment of intrabony defects, furcations,
and gingival recession associated with periodontal defects.
It is specifically contraindicated in areas of acute infection,
although the use of any biomaterial is contraindicated in
infected areas. In addition, it should not be used in areas
in which surgical soft-tissue coverage is necessary but un-
obtainable and in areas in which bone grafting is not advis-
able. Several clinical and animal trials support its use,
which are summarized in Table 2.
Bone Morphogenetic Proteins (BMP-2)
BMPs have an anabolic effect on periodontal tissues
through stimulation of osteoblastic differentiation in hu-
man periodontal ligament cells.6 Some preliminary evi-
dence suggested that BMP-2 could induce periodontal
regeneration, but some adverse healing events such as an-
kylosis and root resorption were also reported.18,19 The
commercially available formx is FDA approved as an alter-
native to autogenous bone grafting for sinus augmentations
and localized alveolar ridge augmentations for defects asso-
ciatedwith extraction sockets.Table3 summarizes the avail-
able evidence on the efficacy of BMP-2 as a biologic agent.
Platelet-Rich Fibrin Glue
Platelet-rich fibrin glue (PRFG) consists of uncoagulated
blood that is centrifuged using a commercially available
system to produce a layer of increased concentrations
of platelets and leukocytes within a fibrin scaffold.20
Platelet-rich fibrin (PRF) contains high amounts of bioac-
tive growth factors to enhance wound healing through in-
creased chemotaxis, proliferation, differentiation, and
angiogenesis.21 PRP was extensively studied in the past,
but PRF is now regarded as having more regenerative po-
tential. PRF is not regulated by the FDA and so there are
no specific approvals for this agent. Table 4 provides in-
formation regarding studies evaluating these regenerative
approaches.
Fibroblast Growth Factor
FGF-2 stimulates angiogenesis and mitosis of mesenchymal
cells and thus may encourage periodontal regeneration.17
Several animal studies support its role as a regenerative
agent,22-25 and one multicenter clinical trial showed im-
proved bone height when using it as an adjunct to peri-
odontal regeneration.26 It is not commercially available
and does not have FDA approval. Table 5 summarizes
the animal studies and one multicenter human clinical trial
evaluating FGF-2.
Parathyroid Hormone
PTH is an endogenous hormone with both catabolic and
anabolic properties in bone, depending on the concentra-
tion and dosing regimen. Animal studies support its ability
to promote bone formation in the oral cavity for both peri-
odontal and implant applications.27-30One randomized hu-
man clinical trial also showed that a commercially available
form of PTHk promoted periodontal regeneration in infrab-
ony defects.12 PTH is FDA approved only for the treatment
of osteoporosis. Table 6 summarizes the available evidence.
Discussion
In deciding on which agent to use, it is important to con-
sider the evidence for a given agent as well as the clinical
scenario. EMD has the largest body of clinical evidence
supporting its use, with many studies showing successful
results for up to 10 years.31-34 Indications for using EMD
are wide, and its use in improving hard- and soft-tissue re-
generation is well supported. It may not be the ideal choice
for use in treating deep andwide defects, because one study
reported that EMD was not beneficial in this situation.35
Furthermore, it is not FDA approved for the treatment
of furcation areas.
PDGF-BB is supported by one of the largest prospective,
randomized, triple-masked, and controlled clinical trials
to assess periodontal regeneration.9 It is indicated for en-
hancing both hard- and soft-tissue regeneration and is asso-
ciatedwith a high degree of improvement in infrabony defect
resolution.36,37 Based on the studies available to date, both
EMDandPDGF-BBappear tohaveminimal safety concerns.
In addition, both show evidence that they accelerate early
healing events, so these may be an ideal choice when faster
healing is desirable (e.g., medically compromised patients).
In terms of available evidence, some studies38,39 failed to
support the ability of PRP to promote hard-tissue regenera-
tion, although there appear to be somebenefits to improving
soft-tissue parameters and accelerating bone maturation.
There is a lackof consensus on the efficacyof PRP,with some
studies showing improved outcomes and others not (see
Table 1). This could be attributable to the wide variation
of growth factors in PRPbased on differences in procurement
technique and patient individuality.40 Once the proper equip-
ment is acquired, PRP requires little cost to operate because
the patient’s blood is used as the regenerative agent. The dis-
advantage of using this technique is that the concentration of
the growth factors within PRP is highly unpredictable.40
BMP-2 has some human trials with long-term follow-up
supporting its use in hard-tissue augmentation applica-
tions.41,42However, no human studies are available regard-
ing its use in periodontal applications. In addition, there are
‡ GEM 21S, BioMimetic Pharmaceuticals, Franklin, TN.
x INFUSE Bone Graft, Medtronic, Memphis, TN.
k Forteo, Eli Lilly, Indianapolis, IN.
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TABLE 2 PDGF-BB
Study Study Design Materials and Methods Conclusions
Nevins et al., 20059 Multicenter human clinical trial 180 patients with an infrabony defect; b-TCP
plus 0.3 mg/mL rhPDGF-BB versus b-TCP
plus 1.0 mg/mL rhPDGF-BB versus b-TCP
0.3 mg/mL rhPDGF-BB resulted in greater
linear bone gain and defect fill at 6 months as
well as faster CAL gain than controls
Howell et al.,199736 Human clinical trial 38 patients, split-mouth design; flap surgery
versus low-dose or high-dose PDGF-BB/IGF-I
High-dose PDGF/IGF-I resulted in significant
bone regeneration
Lynch et al., 199137 Animal study (dogs) 13 dogs with naturally occurring periodontitis,
split-mouth study; PDGF-B/IGF-I versus carrier
PDGF-B/IGF-I resulted in significantly more
new bone, cementum, and PDL formation
IGF ¼ insulin growth factor; PDL ¼ periodontal ligament; rh ¼ recombinant human; TCP ¼ tricalcium phosphate.
TABLE 3 BMP-2
Study Study Design Materials and Methods Conclusions
Triplett et al., 200942 Human clinical trial 160 patients; rhBMP-2 versus autograft for
sinus augmentation
79% success rates in rhBMP-2 group with
comparable outcomes to autograft
Jung et al., 200310 Human clinical trial 11 patients requiring implant placement and
GBR, split-mouth study; xenograft/membrane
versus xenograft/membrane/BMP-2
BMP-2 resulted in more mature lamellar bone
and increased graft-to-bone contact at 6
months
Jung et al., 200941 Human clinical trial Long-term follow-up (3 and 5 years) of
implants from previous 2003 study
No significant differences observed between
groups (100% success rate in both)
Wikesjö et al., 200446 Animal study (dogs) Bilateral surgically created peri-implant
defects; rhBMP-2 versus placebo, both
received ePTFE membrane
rhBMP-2 enhanced GBR for both smooth and
rough surface implants
Saito et al., 200347 Animal study (dogs) 72 surgically created periodontal defects in
four dogs; rhBMP-2 versus rhBMP-2 with
spacer membrane versus placebo
rhBMP-2 had greatest bone formation and CT
attachment but also ankylosis; rhBMP-2 and
spacer membrane minimized ankylosis
CT ¼ connective tissue; ePTFE ¼ expanded polytetrafluoroethylene; rh ¼ recombinant human.
TABLE 1 EMD
Study Study Design Materials and Methods Conclusions
Grusovin and Esposito,
200935
Human clinical trial 30 patients with infrabony defects; EMD
versus placebo
EMD provided no additional benefits in the
treatment of deep and wide infrabony defects
Sculean et al., 200834 Human clinical trial 38 patients; EMD versus GTR versus EMD
plus GTR versus OFD
EMD, GTR, and EMD plus GTR had
significantly greater improvements than OFD
at 10 years
Crea et al., 200831 Human clinical trial 40 patients with infrabony defects; EMD
or GTR using non-resorbable membrane
EMD resulted in significantly improved
clinical and radiographic outcomes for
£36 months
Sculean et al., 200745 Human clinical trial 25 patients with infrabony defects; EMD
or EMD with bioactive glass
Similar and successful results obtained
between the groups for £4 years
Francetti et al., 200532 Multicenter human clinical
trial
195 intrabony defects treated with SPP
flap with EMD
EMD improved the rate and degree of
regeneration
Heijl et al., 199711 Human clinical trial 33 patients with split-mouth design; MWF
versus MWF and EMD
MWF and EMD had significantly greater
radiographic bone fill and CAL gain
MWF ¼ modified Widman flap; OFD ¼ open flap debridement; SPP ¼ simplified papilla preservation flap.
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TABLE 6 PTH
Study Study Design Materials and Methods Conclusions
Bashutski et al., 201012 Human clinical trial 40 patients with infrabony defects; placebo
versus 20 mg PTH 1 to 34 daily for 6 weeks
in conjunction with periodontal surgery
PTH had significantly greater infrabony defect
resolution, CAL gain, and PD reduction
Jung et al., 200729 Animal study (rabbits) Surgically created defects with titanium
cylinders filled with PEG/HA/TCP versus PEG/
PTH versus PEG/PTH/HA/TCP
PTH significantly increased newly formed
bone in calvarial defects
Jung et al., 200728 Animal study (foxhounds) 48 implants in mandible with surgically
created defects; PEG/PTH versus PEG versus
autogenous bone versus control
PTH group achieved greater bone
regeneration
Barros et al., 200327 Animal study (rodents) Ligature-induced periodontitis model; PTH
versus control
PTH protected against periodontitis-
associated bone loss
Miller et al., 199730 Animal study (rodents) Mandibles of ovariectomized rats treated with
PTH versus sham controls
Bone formation was greater in PTH group
HA/TCP ¼ hydroxyapatite/tricalcium phosphate; PD ¼ probing depth; PEG ¼ polyethylene glycol matrix.
TABLE 5 FGF-2
Study Study Design Materials and Methods Conclusions
Kitamura et al., 200826 Multicenter human clinical trial 74 patients with infrabony defects; placebo
versus 0.03% FGF-2 versus 0.1% FGF-2
versus 0.3% FGF-2
No statistically significant differences between
FGF-2 groups and control, except for greater
increase in alveolar bone height between
0.3% FGF-2 and placebo at 36 weeks
Sato et al., 200424 Animal study (dogs) Surgically created defects; 0.1, 1, or 5 mg
basic FGF in collagen gel versus carrier alone
1 mg basic FGF resulted in PDL formation and
newly synthesized cementum at 8 weeks
Takayama et al., 200125 Animal study (primates) 32 surgically created Class II furcation defects in
four primates; 0.1 or 0.4% FGF-2 versus placebo
FGF-2 had significantly greater bone
regeneration and was dose dependent
Hosokawa et al., 200053 Animal study (dogs) FGF-2 versus placebo in surgically created
defects
FGF-2 areas had significantly more bone
regeneration
PDL ¼ periodontal ligament.
TABLE 4 PRF and PRP
Study Study Design Materials and Methods Conclusions
Simon et al., 200948 Animal study (dogs) Four dogs with extracted teeth; PRF versus
PRF plus membrane versus DFDBA plus
membrane versus control
Faster healing in both PRF and PRF plus
membrane groups but graft particles noted in
coronal areas
Mazor et al., 200949 Human case series 25 sinus elevations in 20 patients with PRF No implant failures; histology showed
well-organized and vital bone
Camargo et al., 200950 Human clinical trial 23 patients with infrabony defects, split-mouth
study; BPBM/GTR/PRP versus BPBM/GTR
PRP failed to provide additional benefits as
assessed using surgical reentry at 6 months
Dori et al., 200851 Human clinical trial EMD plus PRP plus NBM versus PRP plus NBM PRP failed to provide additional benefits
Piemontese et al., 200838 Human clinical trial 60 intrabony defects; PRP plus DFDBA versus
DFDBA
PRP resulted in greater PD reductions and
CAL gains at 12 months; no difference in
hard-tissue outcomes
You et al., 200752 Animal study (dogs) Six dogs with three implants each, surgically
created peri-implant defect; autogenous bone
plus PRP or PRFG
Greater BIC with PRFG
BIC ¼ bone-to-implant contact; BPBM ¼ bovine porous bone mineral; DFDBA ¼ demineralized freeze-dried bone allograft; NBM ¼ natural bone mineral; PD¼ probing depth.
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some reports that BMP-2 stimulates root resorption and
ankylosis, so it may be best used in site augmentation
and implant applications.18 Localized inflammation in
the early stage of healing have also been associated with
this agent,42,43 warranting additional study to understand
the mechanism behind this occurrence.
Several animal studies support the role of FGF-2 in pro-
moting bone and cementum formation.23-25 In addition,
one multicenter human clinical trial supports its use in im-
proving bone regeneration.26 Currently, FGF-2 is undergo-
ing multicenter clinical trials to seek FDA approval.
Finally, it is also important toweigh the cost/benefit ratio
because many of these biologic adjuncts have costs associ-
ated with their use. Thus, they are ideally suited to more
complex and challenging cases in which outcomes are less
predictable using traditional approaches.
A recent review44 evaluating bioactive agents found that
EMD (alone or with a bone graft) has positive long-term re-
sults in treating intrabony defects, with the adjunctive use of
a bone graft conferring additional benefits. Intraosseous de-
fects could also be effectively treated with PDGF-BB and
peptide P-15 combined with a bone graft. In this review,44
PRP had variable success. In addition, no bioactive agent
had sufficient evidence to support its use in furcation defects.
Conclusions
Although all biologic agents have shown promise as ad-
juncts to regenerative procedures, certain products may
be better suited to a given clinical situation. Thus, the cli-
nician must carefully evaluate all aspects of the case before
making an informed decision as to which biologic agent
may be best used. n
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11. Heijl L, Heden G, Svärdström G, Ostgren A. Enamel matrix derivative
(EMDOGAIN) in the treatment of intrabony periodontal defects. J Clin
Periodontol 1997;24:705-714.
12. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous
regeneration in the oral cavity. N Engl J Med 2010;363:2396-2405.
13. Lindskog S, Hammarström L. Formation of intermediate cementum. III.
3H-tryptophan and 3H-proline uptake into the epithelial root sheath of
Hertwig in vitro. J Craniofac Genet Dev Biol 1982;2:171-177.
14. Bosshardt DD. Biological mediators and periodontal regeneration: A
review of enamel matrix proteins at the cellular and molecular levels.
J Clin Periodontol 2008; 35(Suppl. 8):87-105.
15. Casarin RC, Ribeiro Edel P, Nociti FH Jr., et al. Enamel matrix
derivative proteins for the treatment of proximal class II furcation
involvements: A prospective 24-month randomized clinical trial. J Clin
Periodontol 2010;37:1100-1109.
16. Hoffmann T, Richter S, Meyle J, et al. A randomized clinical multicentre
trial comparing enamel matrix derivative and membrane treatment of
buccal class II furcation involvement in mandibular molars. Part III. Patient
factors and treatment outcome. J Clin Periodontol 2006;33:575-583.
17. Dereka XE, Markopoulou CE, Vrotsos IA. Role of growth factors on
periodontal repair. Growth Factors 2006;24:260-267.
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